Colorectal Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR109 MIFTS: 42	Colorectal Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma ¹¹ ¹⁴ ¹⁶

Adenocarcinoma of Large Intestine ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0050861

NCIt ⁴⁹ C5105

SNOMED-CT ⁶⁸ 408645001

EFO ¹⁶ EFO_0000365

UMLS ⁷¹ C1319315

Sources

Summaries for Colorectal Adenocarcinoma

Disease Ontology: ¹¹ A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to adenocarcinoma and colorectal adenoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are DNA damage response (only ATM dependent) and mTOR Pathway. The drugs Iron and Hepcidins have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and colon.

Sources

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 524)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	32.4	TP53 KRAS HRAS CEACAM5 CDX2
2	colorectal adenoma	32.0	TP53 MIR31 MIR18A MIR17 MIR143 KRAS
3	adenoma	31.6	TP53 KRAS HRAS CDX2
4	appendix adenocarcinoma	31.3	TP53 KRAS HRAS CEACAM5 CDX2
5	mucinous adenocarcinoma	31.3	TP53 KRAS HRAS CEACAM5 CDX2
6	colonic benign neoplasm	31.1	TP53 MIR18A MIR145 MIR143 KRAS HRAS
7	rectum adenocarcinoma	31.1	TP53 MIR143 KRAS HRAS CEACAM5 CDX2
8	rectal benign neoplasm	31.0	TP53 MIR31 MIR17 MIR145 MIR143 KRAS
9	rectum cancer	31.0	TP53 MIR31 MIR18A MIR17 MIR145 MIR143
10	bladder adenocarcinoma	30.9	TP53 CEACAM5 CDX2
11	lynch syndrome	30.9	TP53 MIR31 MIR18A MIR17 KRAS HRAS
12	gastrointestinal stromal tumor	30.8	TP53 KRAS HRAS H2AC18 CEACAM5
13	gastric adenocarcinoma	30.8	TP53 KRAS HRAS CEACAM5 CDX2
14	signet ring cell adenocarcinoma	30.7	TP53 KRAS HRAS CEACAM5 CDX2
15	exanthem	30.7	KRAS HRAS H2AC18
16	villous adenoma	30.7	TP53 KRAS HRAS CEACAM5 CDX2
17	small intestine adenocarcinoma	30.6	TP53 KRAS HRAS CDX2
18	cholangiocarcinoma	30.6	TP53 KRAS CEACAM5 CDX2
19	lung cancer susceptibility 3	30.5	TP53 MIR31 MIR17 MIR145 MIR143 KRAS
20	gastrointestinal system disease	30.5	MIR31 MIR18A MIR17 MIR145 MIR143 H2AC18
21	wilms tumor 1	30.4	TP53 KRAS HRAS H2AC18 CEACAM5
22	carcinosarcoma	30.4	TP53 KRAS HRAS
23	cystadenocarcinoma	30.4	TP53 KRAS CEACAM5
24	cystadenofibroma	30.4	TP53 KRAS HRAS
25	mismatch repair cancer syndrome	30.3	TP53 KRAS HRAS
26	lung benign neoplasm	30.3	TP53 KRAS HRAS
27	skin melanoma	30.3	TP53 KRAS HRAS H2AC18
28	li-fraumeni syndrome	30.3	TP53 KRAS HRAS H2AC18
29	diffuse large b-cell lymphoma	30.2	MIR18A MIR17 MIR145 MIR143 H2AC18
30	small intestine cancer	30.2	TP53 KRAS HRAS CEACAM5 CDX2
31	skin carcinoma	30.2	TP53 MIR31 MIR18A HRAS H2AC18
32	kidney cancer	30.2	TP53 MIR17 MIR145 H2AC18
33	colon adenoma	30.2	TP53 MIR18A MIR143 KRAS HRAS CDX2
34	stomach disease	30.2	MIR31 MIR18A MIR17 MIR145 MIR143 H2AC18
35	intrahepatic cholangiocarcinoma	30.2	TP53 MIR17 KRAS HRAS H2AC18 CEACAM5
36	gastrointestinal system cancer	30.1	MIR31 MIR18A MIR17 MIR145 MIR143 H2AC18
37	bronchiolo-alveolar adenocarcinoma	30.1	TP53 MIR17 KRAS HRAS CEACAM5 CDX2
38	oral squamous cell carcinoma	30.1	MIR31 MIR17 MIR145 MIR143 HRAS H2AC18
39	thyroid gland cancer	30.1	TP53 MIR17 KRAS HRAS H2AC18 CEACAM5
40	renal cell carcinoma, nonpapillary	30.1	TP53 MIR31 MIR18A MIR17 MIR145 MIR143
41	esophageal cancer	30.1	TP53 MIR31 MIR18A MIR17 MIR145 MIR143
42	hepatocellular carcinoma	30.1	TP53 PIM2 MIR31 MIR18A MIR17 MIR145
43	intestinal disease	30.1	TP53 MIR31 MIR18A MIR17 MIR145 MIR143
44	ovary adenocarcinoma	30.1	TP53 MIR17 KRAS HRAS H2AC18 CEACAM5
45	skin disease	30.0	TP53 MIR31 MIR18A MIR17 KRAS HRAS
46	bladder cancer	30.0	TP53 MIR31 MIR17 MIR145 MIR143 KRAS
47	squamous cell carcinoma, head and neck	30.0	TP53 MIR31 MIR18A MIR17 MIR145 MIR143
48	leukemia, chronic lymphocytic	30.0	TP53 MIR31 MIR17 MIR145 MIR143 KRAS
49	hepatoid adenocarcinoma	30.0	CEACAM5 CDX2
50	pancreatic ductal adenocarcinoma	29.9	TP53 MIR31 MIR18A MIR17 MIR145 MIR143

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:

Sources

Symptoms & Phenotypes for Colorectal Adenocarcinoma

Sources

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved

Phase 4

7439-89-6

29936

Hepcidins

Phase 4

Mitomycin

Approved

Phase 2, Phase 3

50-07-7

5746

Nicotine

Approved

Phase 3

54-11-5

942 89594

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Glutamic acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Chlorotrianisene

Investigational, Withdrawn

Phase 3

569-57-3

11289

Calciferol

Phase 3

Immunoglobulins, Intravenous

Phase 3

Immunoglobulins

Phase 3

Antibodies, Monoclonal

Phase 3

Antibodies

Phase 3

Hematinics

Phase 3

Formyltetrahydrofolates

Phase 3

Tetrahydrofolates

Phase 3

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Lapatinib

Approved, Investigational

Phase 2

231277-92-2, 388082-78-8

208908

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Cetuximab

Approved

Phase 2

205923-56-4

Vancomycin

Approved

Phase 2

1404-90-6

14969

Framycetin

Approved, Experimental, Vet_approved

Phase 2

1404-04-2, 119-04-0, 3947-65-7

413349 8378

Metronidazole

Approved

Phase 2

443-48-1, 69198-10-3

4173

Obinutuzumab

Approved, Investigational

Phase 1, Phase 2

949142-50-1

Paclitaxel

Approved, Vet_approved

Phase 1, Phase 2

33069-62-4

36314

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Trametinib

Approved

Phase 2

871700-17-3

11707110

Dimethyl sulfoxide

Approved, Vet_approved

Phase 2

67-68-5

679

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760

Tremelimumab

Approved, Investigational

Phase 1, Phase 2

745013-59-6

Ipilimumab

Approved

Phase 2

477202-00-9

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Hydroquinone

Approved, Investigational

Phase 2

123-31-9

785

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751 657237

Trifluridine

Approved, Investigational

Phase 2

70-00-8

6256

Tucatinib

Approved, Investigational

Phase 2

937263-43-9

51039094

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Atezolizumab

Approved, Investigational

Phase 1, Phase 2

1380723-44-3

Durvalumab

Approved, Investigational

Phase 1, Phase 2

1428935-60-7

Dopamine

Approved

Phase 1, Phase 2

62-31-7, 51-61-6

681

Metamfetamine

Approved, Illicit, Withdrawn

Phase 1, Phase 2

537-46-2

10836

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Sulindac

Approved, Investigational

Phase 2

38194-50-2

5352 1548887

Ceritinib

Approved

Phase 2

1032900-25-6

57379345

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Interventional clinical trials:

(show top 50) (show all 143)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
2	TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy	Unknown status	NCT03783559	Phase 3	TACE;chemotherapy±target therapy
3	A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases	Unknown status	NCT03125161	Phase 3	HAI;chemotherapy ± target therapy
4	A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma	Completed	NCT02788279	Phase 3	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
5	A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma	Completed	NCT00623805	Phase 3	Bevacizumab;Capecitabine;Oxaliplatin
6	A Multicenter，Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma	Completed	NCT02390947	Phase 3	Famitinib;Placebo
7	The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial	Completed	NCT00265356	Phase 3
8	Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superiority Study	Recruiting	NCT02758951	Phase 2, Phase 3
9	Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer	Recruiting	NCT02997228	Phase 3	Atezolizumab;Fluorouracil;Leucovorin;Oxaliplatin
10	Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)	Recruiting	NCT04094688	Phase 3	Bevacizumab;Oxaliplatin;Leucovorin Calcium;Fluorouracil;Irinotecan Hydrochloride;Irinotecan
11	Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab	Terminated	NCT03300609	Phase 3	Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
12	Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial	Withdrawn	NCT03708536	Phase 3	S-1;Bevacizumab;Capecitabine
13	Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma	Unknown status	NCT00544011	Phase 2	capecitabine;fluorouracil;irinotecan hydrochloride
14	Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma	Unknown status	NCT00027833	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
15	A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment	Unknown status	NCT01067053	Phase 2	bevacizumab, capecitabine, oxaliplatin
16	A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma	Unknown status	NCT01552967	Phase 2	Capecitabine
17	A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-line Therapy for Patients With Metastatic Colorectal Cancer	Unknown status	NCT04380103	Phase 1, Phase 2	XELOXIRI/Bevacizumab
18	A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens	Completed	NCT00419159	Phase 2	Everolimus (RAD001)
19	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma	Completed	NCT01900717	Phase 2	LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
20	Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .	Completed	NCT02788006	Phase 2	Regorafenib 160 mg
21	Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70	Completed	NCT00104689	Phase 2	capecitabine;oxaliplatin
22	Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma	Completed	NCT00168155	Phase 2	perioperative chemotherapy
23	Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease	Completed	NCT00890305	Phase 2	CT-011;FOLFOX
24	A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)	Completed	NCT00574171	Phase 2	lapatinib;Capecitabine
25	A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver	Completed	NCT00149396	Phase 1, Phase 2	NV1020
26	A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma	Completed	NCT00034190	Phase 2	S-8184 Paclitaxel Injectable Emulsion
27	A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma	Completed	NCT00025350	Phase 2	gefitinib
28	Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma.	Completed	NCT02181465	Phase 2
29	A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	Completed	NCT02870920	Phase 2	Tremelimumab;Durvalumab
30	Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO	Completed	NCT01417494	Phase 2	Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
31	A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors	Completed	NCT02599324	Phase 1, Phase 2	ibrutinib;everolimus;paclitaxel;docetaxel;cetuximab;pembrolizumab
32	BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer	Completed	NCT02292758	Phase 2	Irinotecan
33	Regorafenib Assessment in Refractory Advanced Colorectal Cancer	Completed	NCT01929616	Phase 2	regorafenib
34	Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus	Completed	NCT00597506	Phase 2	Bevacizumab;Everolimus
35	A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Completed	NCT00165217	Phase 2	Capecitabine;Thalidomide
36	A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)	Recruiting	NCT04117945	Phase 2	Irinotecan;Regorafenib
37	A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients	Recruiting	NCT03087071	Phase 2	Trametinib
38	A Phase 1b/2 Study of VS-6766 and Cetuximab in Patients With Advanced KRAS Mutated Colorectal Cancer	Recruiting	NCT05200442	Phase 1, Phase 2	VS-6766;Cetuximab
39	A Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Tyrosine Kinase Inhibitor (TKI) in Combination With Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.	Recruiting	NCT04483219	Phase 2	TKI ± anti-PD-1 antibody
40	Pilot Trial of Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-Responders	Recruiting	NCT04729322	Phase 2	Fecal Microbiota Transplantation Capsule;Metronidazole;Neomycin;Vancomycin
41	An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290, A Fibroblast Activation Protein-A (FAP) Targeted 4-1BB Ligand (CD137L), In Combination With Cibisatamab With Obinutuzumab Pre-Treatment, In Participants With Previously Treated, Metastatic, Microsatellite-stable Colorectal Adenocarcinoma With High CEACAM5 Expression	Recruiting	NCT04826003	Phase 1, Phase 2	RO7122290;Cibisatamab;Obinutuzumab
42	A Phase II Study Evaluating FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation	Recruiting	NCT03584711	Phase 2
43	Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors	Recruiting	NCT02185443	Phase 2
44	A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy	Recruiting	NCT04111172	Phase 2
45	A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors	Recruiting	NCT04731467	Phase 1, Phase 2	CM-24 and Nivolumab - Dose Escalation;CM-24 and Nivolumab - Expansion;CM-24, Nivolumab, and Nab paclitaxel - Expansion;CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
46	A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal Cancer	Recruiting	NCT04457284	Phase 2	Temozolomide (TMZ);Cisplatin;Nivolumab
47	The Role of Multimodality Management in Risk-Stratified Patients With Lung-Limited Metastatic Colorectal Cancer	Recruiting	NCT03599752	Phase 2	Chemotherapy
48	A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine	Recruiting	NCT04894123	Phase 2	Trifluridine/Tipiracil;Oxaliplatin
49	CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio- Marker-driven Cetuximab-based Treatment Regimen Over 3 Treatment Lines in mCRC Patients With RAS/BRAF wt Tumors at Start of First Line	Recruiting	NCT05312398	Phase 2	Cetuximab;FOLFIRI;FOLFOX regimen;Irinotecan
50	A Phase 1/2 Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer	Recruiting	NCT04474470	Phase 1, Phase 2	NT219;NT219 and ERBITUX® - Dose Escalation;NT219 and ERBITUX® - Expansion

Search NIH Clinical Center for Colorectal Adenocarcinoma

Sources

Genetic Tests for Colorectal Adenocarcinoma

Sources

Anatomical Context for Colorectal Adenocarcinoma

Organs/tissues related to Colorectal Adenocarcinoma:

MalaCards : Liver, Lymph Node, Colon, Lung, Endothelial, Thyroid, Kidney

Sources

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 4250)

#	Title	Authors	PMID	Year
1	A case of rapidly progressing and poorly differentiated Ip-type early-stage colorectal adenocarcinoma. ⁶²	Tsubomoto A...Hamahata Y	36310664	2023
2	Phytochemical profile, in vitro bioaccessibility, and anticancer potential of golden root (Rhodiola rosea L.) extracts. ⁶²	Seczyk L...Kolodziej B	36332586	2023
3	Topical systems for the controlled release of antineoplastic Drugs: Oxidized Alginate-Gelatin Hydrogel/Unilamellar vesicles. ⁶²	Stagnoli S...Boccaccini AR	36303362	2023
4	Germline gain-of-function MMP11 variant results in an aggressive form of colorectal cancer. ⁶²	Martin-Morales L...Gutierrez-Uzquiza A	36093604	2023
5	Proteomic profiling reveals an association between ALDH and oxidative phosphorylation and DNA damage repair pathways in human colon adenocarcinoma stem cells. ⁶²	Wang Y...Vasiliou V	36162455	2022
6	Toxicology assessment of manganese oxide nanomaterials with enhanced electrochemical properties using human in vitro models representing different exposure routes. ⁶²	Fernandez-Pampin N...Tamayo-Ramos JA	36471154	2022
7	Influence of permeability enhancers on the paracellular permeability of metformin hydrochloride and furosemide across Caco-2 cells. ⁶²	Gulsun T...Sahin S	36459686	2022
8	Krukenberg tumor in pregnancy: a rare case and review of the literature. ⁶²	Goidescu IG...Mure?an D	34470118	2022
9	Experimental validation of in silico analysis estimated the reverse effect of upregulated hsa-miR-106a-5p and hsa-miR-223-3p on SLC4A4 gene expression in Iranian patients with colorectal adenocarcinoma by RT-qPCR. ⁶²	Ranjbaran J...Chamani E	36468451	2022
10	Osteopontin expression in the invasive front stroma of colorectal adenocarcinoma is associated with tumor budding and prognosis. ⁶²	Nakajima T...Ota H	36332325	2022
11	Major vascular reconstruction in colorectal adenocarcinoma and retroperitoneal sarcoma: A retrospective study of safety and margins in a tertiary referral centre. ⁶²	Apte SS...Heriot AG	36270156	2022
12	Efficacy of adoptively transferred allogeneic CIK cells on colorectal cancer: Augmentative antitumoral effects of GvHD. ⁶²	Muhammadnejad S...Ahmadbeigi N	36463696	2022
13	Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). ⁶²	Symonds L...Cohen SA	35412430	2022
14	Cancer-associated fibroblasts derived extracellular vesicles promote angiogenesis of colorectal adenocarcinoma cells through miR-135b-5p/FOXO1 axis. ⁶²	Dai X...Dong M	35100092	2022
15	Novel Ru(II)-bipyridine/phenanthroline-lapachol complexes as potential anti-cancer agents. ⁶²	De Grandis RA...Resende FA	36155170	2022
16	DNA Extracted from Cytologic Slides Is a Valuable Source for PCR-Based Molecular Tests. ⁶²	Kwon HS...Kim JY	36455541	2022
17	Acteoside alleviates dextran sulphate sodium‑induced ulcerative colitis via regulation of the HO‑1/HMGB1 signaling pathway. ⁶²	Guo W...Du S	36281914	2022
18	Bioinformatics analysis on differentially expressed genes between colorectal adenoma and colorectal adenocarcinoma. ⁶²	Ding N...He Y	36031809	2022
19	Identification of odontogenic ameloblast associated as a novel target gene of the Wnt/β-catenin signaling pathway. ⁶²	Yamaguchi K...Furukawa Y	36382598	2022
20	A Canadian Provincial Screening Program for Lynch Syndrome. ⁶²	Stone JK...Singh H	36219179	2022
21	DNMT1 Mediated CAHM Repression Promotes Glioma Invasion via SPAK/JNK Pathway. ⁶²	Xu Y...Zhao B	34227028	2022
22	All-trans retinoic acid enhances the anti-tumour effects of fimaporfin-based photodynamic therapy. ⁶²	Wong JJW...Selbo PK	36108391	2022
23	Rectal cancer combined with abdominal tuberculosis: A case report. ⁶²	Liu PG...Feng PF	36387825	2022
24	Antimicrobial, cytotoxic, and insulin-releasing activities of the amphibian host-defense peptide ocellatin-3N and its L-lysine-substituted analogs. ⁶²	Conlon JM...Abdel-Wahab YHA	36426386	2022
25	Flat colorectal adenocarcinoma: a worrisome false negative of artificial intelligence-assisted colonoscopy. ⁶²	Lafeuille P...Pioche M	35168276	2022
26	Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis. ⁶²	Peng X...Zhang A	36288643	2022
27	In vitro toxicity and internalization of gold nanoparticles (AuNPs) in human epithelial colorectal adenocarcinoma (Caco-2) cells and the human skin keratinocyte (HaCaT) cells. ⁶²	Magogotya M...Gulumian M	36462792	2022
28	Antiproliferative and Microtubule-stabilizing Activities of Two Iboga-vobasine Bisindoles Alkaloids from Tabernaemontana corymbosa in Colorectal Adenocarcinoma HT-29 Cells. ⁶²	Tan CH...Sim KS	35100653	2022
29	Colorectal adenocarcinoma with enteroblastic differentiation. Report of one case with lacunar growth pattern, microcalcifications, osseous metaplasia, and metachronous involvement of sigma and appendix. ⁶²	Suarez-Vilela D...Izquierdo FM	36321408	2022
30	Epidermotropic Cutaneous Metastasis of Colonic Adenocarcinoma Presenting as a Sister Mary Joseph Nodule. ⁶²	Jimenez A...Goodwin B	35925573	2022
31	Molecular characterization of adenocarcinomas arising in the urinary bladder following augmentation cystoplasty: a multi-institutional study. ⁶²	Stohr BA...Osunkoya AO	36108931	2022
32	Analysis of bioactive compounds using LC-ESI-MS/MS, cytotoxic, antimicrobial effects, and enzyme activities from Cyclotrichium origanifolium. ⁶²	Aktepe N...Jahan I	36366959	2022
33	Towards personalized antibody cancer therapy: development of a microfluidic cell culture device for antibody selection. ⁶²	Condelipes PGM...Conde JP	36349999	2022
34	Isothiocyanate-Rich Extracts from Cauliflower (Brassica oleracea Var. Botrytis) and Radish (Raphanus sativus) Inhibited Metabolic Activity and Induced ROS in Selected Human HCT116 and HT-29 Colorectal Cancer Cells. ⁶²	Cuellar-Nunez ML...Camacho-Calderon N	36429638	2022
35	Effects of electrospun fiber curcumin on bisphenol A exposed Caco-2 cells. ⁶²	Turgut Y...Acarturk F	34696662	2022
36	New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: Synthesis and pharmacological effects. ⁶²	Robello M...Bocci G	35904260	2022
37	Inflammatory Response in Caco-2 Cells Stimulated with Anisakis Messengers of Pathogenicity. ⁶²	Bellini I...Cavallero S	36297271	2022
38	Risk factors for small intestinal adenocarcinomas that are common in the proximal small intestine. ⁶²	Fujimori S...Iwakiri K	36338888	2022
39	Tuning the Cell-Adhesive Properties of Two-Component Hybrid Hydrogels to Modulate Cancer Cell Behavior, Metastasis, and Death Pathways. ⁶²	Isik M...Derkus B	36136959	2022
40	C. spinosa L. subsp. rupestris Phytochemical Profile and Effect on Oxidative Stress in Normal and Cancer Cells. ⁶²	Bacchetti T...Emanuelli M	36235028	2022
41	Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer. ⁶²	Feng ML...Sun MJ	36310706	2022
42	Incidence and Survival in Synchronous and Metachronous Liver Metastases From Colorectal Cancer. ⁶²	Reboux N...Bouvier AM	36239935	2022
43	Nanoplatforms for Irinotecan Delivery Based on Mesoporous Silica Modified with a Natural Polysaccharide. ⁶²	Brezoiu AM...Berger D	36234345	2022
44	Chylomicron production is repressed by RPTOR knockdown, R-α-lipoic acid and 4-phenylbutyric acid in human enterocyte-like Caco-2 cells. ⁶²	He B...Moreau R	35691593	2022
45	Synthesis of 4-Hydroxycoumarin-Based Triazoles/Oxadiazoles as Novel Anticancer Agents. ⁶²	Hashemi SM...Emami S	36181443	2022
46	Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges. ⁶²	Lang D...Ciombor KK	36240852	2022
47	Enhanced Antioxidant and Anti-Inflammatory Effects of Self-Nano and Microemulsifying Drug Delivery Systems Containing Curcumin. ⁶²	Jozsa L...Feher P	36235189	2022
48	Transformer-based unsupervised contrastive learning for histopathological image classification. ⁶²	Wang X...Han X	35952419	2022
49	Effects of selected condensed tannins on Cryptosporidium parvum growth and proliferation in HCT-8 cell cultures. ⁶²	Woolsey ID...Enemark HL	35995247	2022
50	Predictors of Small Bowel Obstruction Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. ⁶²	Jedrzejko N...Hamilton TD	35852704	2022

Sources

Genes for Colorectal Adenocarcinoma

Genes related to Colorectal Adenocarcinoma (0 elite genes):

(show top 50) (show all 56)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	FABP6	Fatty Acid Binding Protein 6	Protein Coding	19.35	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
2	FGFBP1	Fibroblast Growth Factor Binding Protein 1	Protein Coding	15.93	GeneCards inferred via : Publications Summaries (show sections)
3	PIM2	Pim-2 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	15.48	GeneCards inferred via : Functions Expressions (show sections)
4	APOBEC3A	Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A	Protein Coding	10.57	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
5	UTP23	UTP23 Small Subunit Processome Component	Protein Coding	10.51	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
6	TINAGL1	Tubulointerstitial Nephritis Antigen Like 1	Protein Coding	10	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
7	NPW	Neuropeptide W	Protein Coding	9.95	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
8	H2AC18	H2A Clustered Histone 18	Protein Coding	8.26	DISEASES inferred ¹⁴ ¹⁴
9	MIR18A	MicroRNA 18a	RNA Gene	7.89	DISEASES inferred ¹⁴ ¹⁴
10	MIR143	MicroRNA 143	RNA Gene	7.82	DISEASES inferred ¹⁴ ¹⁴
11	MIR17	MicroRNA 17	RNA Gene	7.74	DISEASES inferred ¹⁴ ¹⁴
12	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	7.7	DISEASES inferred ¹⁴
13	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	7.67	DISEASES inferred ¹⁴
14	LOC111674464	CFTR Intron 1 Enhancer	Functional Element	7.6	GeneCards inferred via : Summaries (show sections)
15	MIR145	MicroRNA 145	RNA Gene	7.54	DISEASES inferred ¹⁴ ¹⁴
16	TP53	Tumor Protein P53	Protein Coding	7.49	DISEASES inferred ¹⁴
17	CDX2	Caudal Type Homeobox 2	Protein Coding	7.43	DISEASES inferred ¹⁴
18	MIR31	MicroRNA 31	RNA Gene	7.3	DISEASES inferred ¹⁴ ¹⁴
19	MIR3184	MicroRNA 3184	RNA Gene	7.23	DISEASES inferred ¹⁴ ¹⁴
20	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	7.1	DISEASES inferred ¹⁴
21	CARD11	Caspase Recruitment Domain Family Member 11	Protein Coding	7.09	GeneCards inferred via : Expressions (show sections)
22	DEDD2	Death Effector Domain Containing 2	Protein Coding	7.09	GeneCards inferred via : Expressions (show sections)
23	NDOR1	NADPH Dependent Diflavin Oxidoreductase 1	Protein Coding	7.09	GeneCards inferred via : Expressions (show sections)
24	NOX5	NADPH Oxidase 5	Protein Coding	7.09	GeneCards inferred via : Expressions (show sections)
25	NPB	Neuropeptide B	Protein Coding	7.09	GeneCards inferred via : Expressions (show sections)
26	CTNNB1	Catenin Beta 1	Protein Coding	7.08	DISEASES inferred ¹⁴
27	EGFR	Epidermal Growth Factor Receptor	Protein Coding	7.05	DISEASES inferred ¹⁴
28	KRT7	Keratin 7	Protein Coding	7	DISEASES inferred ¹⁴
29	MLH1	MutL Homolog 1	Protein Coding	6.97	DISEASES inferred ¹⁴
30	MIR193A	MicroRNA 193a	RNA Gene	6.77	DISEASES inferred ¹⁴ ¹⁴
31	MIR29A	MicroRNA 29a	RNA Gene	6.68	DISEASES inferred ¹⁴ ¹⁴
32	CDH1	Cadherin 1	Protein Coding	6.67	DISEASES inferred ¹⁴
33	MSH6	MutS Homolog 6	Protein Coding	6.65	DISEASES inferred ¹⁴
34	MSH2	MutS Homolog 2	Protein Coding	6.64	DISEASES inferred ¹⁴
35	CRYGC	Crystallin Gamma C	Protein Coding	6.63	DISEASES inferred ¹⁴
36	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.6	DISEASES inferred ¹⁴
37	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.6	DISEASES inferred ¹⁴
38	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	6.59	DISEASES inferred ¹⁴
39	KRT20	Keratin 20	Protein Coding	6.57	DISEASES inferred ¹⁴
40	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.56	DISEASES inferred ¹⁴
41	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.52	DISEASES inferred ¹⁴
42	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	6.46	DISEASES inferred ¹⁴
43	ACTB	Actin Beta	Protein Coding	6.44	DISEASES inferred ¹⁴
44	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	6.4	DISEASES inferred ¹⁴
45	BCL2	BCL2 Apoptosis Regulator	Protein Coding	6.39	DISEASES inferred ¹⁴
46	SMAD4	SMAD Family Member 4	Protein Coding	6.36	DISEASES inferred ¹⁴
47	CASP3	Caspase 3	Protein Coding	6.32	DISEASES inferred ¹⁴
48	CCND1	Cyclin D1	Protein Coding	6.29	DISEASES inferred ¹⁴
49	MIR126	MicroRNA 126	RNA Gene	6.26	DISEASES inferred ¹⁴ ¹⁴
50	SATB2	SATB Homeobox 2	Protein Coding	6.2	DISEASES inferred ¹⁴

Sources

Variations for Colorectal Adenocarcinoma

Sources

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Sources

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	DNA damage response (only ATM dependent) ⁷⁴	11.59	TP53 KRAS HRAS
2	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.4	TP53 KRAS HRAS
3	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.33	MIR17 MIR145 MIR143
4	Head and neck squamous cell carcinoma ⁷⁴	11.2	TP53 KRAS HRAS
5	Transcription_Transcription factor Tubby signaling pathways ²²	11.02	TP53 KRAS HRAS
6	miRNAs involved in DNA damage response ⁷⁴	10.85	TP53 MIR18A MIR17 MIR145 MIR143
7	Bladder cancer ⁷⁴	10.73	TP53 KRAS HRAS
8	TNF-alpha signaling pathway ⁷⁴ Show member pathways RAS GTPase cycle mutants ⁶⁶ Signaling by RAS GAP mutants ⁶⁶ Signaling by RAS GTPase mutants ⁶⁶	10.45	KRAS HRAS

Sources

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.36	MIR3184 MIR31 MIR18A MIR17 MIR145 MIR143

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	aorta smooth muscle tissue morphogenesis	GO:0060414	9.26	MIR145 MIR143
2	regulation of phenotypic switching	GO:1900239	9.16	MIR145 MIR143
3	positive regulation of pulmonary blood vessel remodeling	GO:1905111	8.96	MIR17 MIR143
4	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	8.62	MIR145 MIR143

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA base-pairing translational repressor activity	GO:1903231	9.35	MIR31 MIR18A MIR17 MIR145 MIR143
2	mRNA 3'-UTR binding	GO:0003730	9.23	UTP23 TP53 MIR31 MIR17 MIR145 MIR143